[1.]Xu X, Sun Q, Liang X et al. Mechanisms of relapse after CD19 CAR T-Cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol 2019 ; 10 : 2664.
[2.]Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018 ; 378 : 449-59.
[3.]Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 2019 ; 16 : 372-85.
André I, Simons L, Ma K, et al. Ex vivo generated human T-Lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic stem cell transplantation or after gene therapy. Bone Marrow Transplant 2019 ; 54(suppl_2) : 749-55.
Baird JH, Epstein DH, Tamaresis JS, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Adv 2021 ; 5 : 143-55.
D’Agostino M, Raje, N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia 2020 ; 34 : 21-34.
de Koning C, Prockop S, van Roessel I, et al. CD4+ T-Cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation. Blood 2021 ; 137(6) : 848-55.
Gaudeaux P, Moirangthem RD, Bauquet A, et al. T-Cell progenitors as a new immunotherapy to bypass hurdles of allogeneic hematopoietic stem cell transplantation. Front Immunol 2022 ; 13 : 956919.
Gaudeaux P, Moirangthem RD, Rault P, et al. Manufacturing of human T-lymphoid progenitors from two different hematopoietic stem cell sources and perspective for new immunotherapies. J Cell Immunol 2022 ; 4(4) : 149-57.
Goldberg JD, Zheng J, Ratan R, et al. Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. Leuk Lymphoma 2017 ; 58(8) : 1859-71.
Maus M. CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia. Lancet 2021 ; 398 : 466-7.
Moirangthem RD, Ma K, Lizot S, et al. A DL-4- and tnfα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors. Cell Mol Immunol 2021 ; 18(7) : 1662-76.
Shah NN, Johnson BD, Schneider D, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med 2020 ; 26 : 1569-75.
Wudhicarn K, Palomba ML, Pennisi M, et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J 2020 ; 10 : 79.